Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo- and active-controlled Phase 2 study of 3% P32/98 cream in plaque psoriasis
2006-005344-83Phase 2Terminated
- Sponsor
- Vivoryon Therapeutics N.V.
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of P32/98 in psoriasis (3 arms), sponsored by Vivoryon Therapeutics N.V. Primary endpoint: Thickness of epidermis assessed by high-frequency ultrasound. Started Nov 2006; status: terminated.
02
Drugs
P32/98
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2006-005344-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005344-83.